Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/08/23
What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing'Zacks Investment Research • 10/09/23
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ CancersGlobeNewsWire • 09/06/23
Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/07/23
Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant CancersGlobeNewsWire • 07/24/23
Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid TumorsGlobeNewsWire • 07/10/23
Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/09/23
Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingGlobeNewsWire • 04/18/23
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant CancersGlobeNewsWire • 04/03/23
Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/27/23
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual MeetingGlobeNewsWire • 03/15/23
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Tango Therapeutics, Inc (TNGX) InvestigationBusiness Wire • 02/21/23